Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

NCT06031480 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Anlotinib and TQB2450

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]